Strategic Tau Leadership Leverage Axon’s position as a clinical-stage leader in tau-targeted therapies to position your solutions as enabling platform support for their two major platform trials (ATP for Alzheimer's early stages and PSP tauopathies), highlighting tools and services that streamline trial operations, biomarker analytics, and patient recruitment.

Global Platform Trials Axon is expanding into two international platform trials starting in 2026. This presents opportunities to provide global trial management, site networks, regulatory consulting, data management, and biomarker assay partnerships that support multi-country enrollment and harmonization.

Biomarker and Imaging Focus With biomarker endpoints (NfL, GFAP) and MRI volumetry as validated efficacy signals, offer advanced imaging, biomarker assay development, and centralized analytics services to strengthen their disease-modifying evidence generation and regulatory submissions.

Diverse Pipeline Synergy Axon’s portfolio includes AADvac1, AADvac2, and small-molecule tau programs. Propose collaborations around companion diagnostics, translational research tools, or partnering opportunities to extend their platform across vaccine, antibody, and small-molecule modalities.

Regulatory and Market Enablement Given their clinical-stage status and global trials, there is demand for regulatory strategists, health economics outcomes research, payer engagement, and market access support to facilitate later-stage approvals and reimbursement in multiple regions.